145 related articles for article (PubMed ID: 29197875)
1. Efficacy and Tolerability of Leuprorelin Acetate (Eligard®) in Daily Practice in Germany: Pooled Data from 2 Prospective, Non-Interventional Studies with 3- or 6-Month Depot Formulations in Patients with Advanced Prostate Cancer.
Ohlmann CH; Gross-Langenhoff M
Urol Int; 2018; 100(1):66-71. PubMed ID: 29197875
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
Braeckman J; Michielsen D
Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
[TBL] [Abstract][Full Text] [Related]
3. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients.
Tunn UW
BMC Urol; 2011 Jul; 11():15. PubMed ID: 21801354
[TBL] [Abstract][Full Text] [Related]
4. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
[TBL] [Abstract][Full Text] [Related]
5. A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer.
Perez-Marreno R; Chu FM; Gleason D; Loizides E; Wachs B; Tyler RC
Clin Ther; 2002 Nov; 24(11):1902-14. PubMed ID: 12501882
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
[TBL] [Abstract][Full Text] [Related]
7. Two innovative pharmaceutical forms of leuprorelin: results from 818 patients with advanced prostate cancer.
Gravel P; Samland D; Löffler M; Maier S; Panozzo M; Muenzberg M
Adv Ther; 2013 Mar; 30(3):271-85. PubMed ID: 23460040
[TBL] [Abstract][Full Text] [Related]
8. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
9. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.
Crawford ED; Moul JW; Sartor O; Shore ND
Expert Opin Drug Metab Toxicol; 2015; 11(9):1465-74. PubMed ID: 26293510
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.
Suzuki K; Namiki M; Fujimoto T; Takabayashi N; Kudou K; Akaza H
Jpn J Clin Oncol; 2015 Dec; 45(12):1168-74. PubMed ID: 26486824
[TBL] [Abstract][Full Text] [Related]
11. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results.
Jocham D
Urol Int; 1998; 60 Suppl 2():18-24; discussion 35. PubMed ID: 9607554
[TBL] [Abstract][Full Text] [Related]
12. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer.
Tunn UW; Bargelloni U; Cosciani S; Fiaccavento G; Guazzieri S; Pagano F
Urol Int; 1998; 60 Suppl 1():9-16; discussion 16-7. PubMed ID: 9563139
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate.
Khan MS; O'Brien A
Urol Int; 1998; 60(1):33-40. PubMed ID: 9519419
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of leuprorelin acetate depot for prostate cancer. The German Leuprorelin Study Group.
Kienle E; Lübben G
Urol Int; 1996; 56 Suppl 1():23-30. PubMed ID: 8776814
[TBL] [Abstract][Full Text] [Related]
15. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer.
Berges R; Bello U
Curr Med Res Opin; 2006 Apr; 22(4):649-55. PubMed ID: 16684425
[TBL] [Abstract][Full Text] [Related]
16. Eligard: leuprolide acetate in a novel sustained-release delivery system.
Sartor O
Urology; 2003 Feb; 61(2 Suppl 1):25-31. PubMed ID: 12667884
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Leuprorelide acetate (Eligard®) in daily practice in Brazil: a retrospective study with depot formulations in patients with prostate cancer.
de Freitas CSM; Soares AN
Int Braz J Urol; 2020; 46(3):383-389. PubMed ID: 32167701
[TBL] [Abstract][Full Text] [Related]
18. [The role of a 6-month depot form of hormone therapy in the treatment of advanced hormone-dependent prostate cancer: Results from the 'ELIRE' observational study].
Ouzaid I; Rouprêt M
Prog Urol; 2011 Nov; 21(12):866-74. PubMed ID: 22035913
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study.
Marberger M; Kaisary AV; Shore ND; Karlin GS; Savulsky C; Mis R; Leuratti C; Germa JR
Clin Ther; 2010 Apr; 32(4):744-57. PubMed ID: 20435244
[TBL] [Abstract][Full Text] [Related]
20. A clinical study of 22.5 mg. La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer.
Chu FM; Jayson M; Dineen MK; Perez R; Harkaway R; Tyler RC
J Urol; 2002 Sep; 168(3):1199-203. PubMed ID: 12187267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]